| There were no cases of moderate or serious illness or hospitalization among people who received the two-dose regimen during a study conducted by the Gaithersburg, Md., biotechnology company, and few cases of even mild illness. The vaccine could become available in the summer if regulators clear it for emergency use. | 
No comments:
Post a Comment